
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna's projected product sales are expected to grow from $1.73 billion in 2025 to $2.15 billion in 2026, indicating a robust revenue trajectory fueled by its expanding pipeline of mRNA development candidates across various therapeutic areas. The company has also improved its gross margins from a low of 30% in 2023 back to 50% in 2025, alongside enhancements in manufacturing efficiency that could support a further increase of 10% over the next three years. Additionally, a recent $1.5 billion debt deal strengthens Moderna's balance sheet, providing increased flexibility to navigate uncertainties and capitalize on future opportunities.
Bears say
Moderna's negative outlook is primarily driven by a significant decline in COVID vaccine sales, dropping from $18 billion in 2022 to an anticipated $6.7 billion in 2023, alongside reduced revenue guidance for 2025 due to waning vaccination rates and competitive pressures. The potential for future revenue generation is further constrained by limited success in expanding its vaccine pipeline beyond respiratory diseases and growing uncertainty regarding European sales, particularly with ongoing negotiations for tender agreements. Consequently, the firm's projected enterprise value has decreased from $22.12 billion to $21.53 billion, reflecting a cautious stance on its long-term growth potential in the evolving pharmaceutical landscape.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares